Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Caron A Jacobson,Frederick L Locke,David B Miklos,Julie M Vose,Yi Lin,Lihua E Budde,David G Maloney,Samantha Jaglowski,Peter A Riedell,Lazaros J Lekakis,Miguel-Angel Perales,Jenny J Kim,Jun Kawashima,Yin Yang,John M Rossi,Lovely Goyal,Sattva S Neelapu

doi:10.1182/blood-2020-136136

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Caron A Jacobson, Frederick L Locke + Show 15 more

Open Access

https://doi.org/10.1182/blood-2020-136136

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 3

Affiliation: Dana-Farber Cancer Institute, Moffitt Cancer Center, Stanford University, University of Nebraska Medical Center, Mayo Clinic, City Of Hope National Medical Center, Fred Hutch Cancer Center, The Ohio State University, University of Chicago Medical Center, Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center

#Research Funding #Gilead Company + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.